Affymax Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2009
2010
2011
2012
2013
Sales/Revenue
114,899.00
112,521.00
47,720.00
94,370.00
1,369.00
Cost of Goods Sold (COGS) incl. D&A
-
-
-
-
722.00
Gross Income
-
-
-
-
647.00
SG&A Expense
191,725.00
124,757.00
106,944.00
137,393.00
38,664.00
EBIT
78,942.00
14,448.00
61,406.00
90,039.00
38,017.00
Unusual Expense
-
-
-
4,000.00
19,866.00
Non Operating Income/Expense
171.00
239.00
15.00
1,966.00
42,845.00
Interest Expense
105.00
140.00
144.00
1,442.00
1,565.00
Pretax Income
77,942.00
14,074.00
61,366.00
93,438.00
16,582.00
Income Tax
1,411.00
1.00
1.00
26.00
2,158.00
Consolidated Net Income
76,531.00
14,075.00
61,367.00
93,412.00
14,424.00
Net Income
76,531.00
14,075.00
61,367.00
93,412.00
14,424.00
Net Income After Extraordinaries
76,531.00
14,075.00
61,367.00
93,412.00
14,424.00
Net Income Available to Common
76,531.00
14,075.00
61,367.00
93,412.00
14,424.00
EPS (Basic)
4.06
0.57
1.84
2.57
0.39
Basic Shares Outstanding
18,865.00
24,488.00
33,288.00
36,342.00
37,448.00
EPS (Diluted)
4.06
0.57
1.84
2.57
0.39
Diluted Shares Outstanding
18,865.00
24,488.00
33,288.00
36,342.00
37,448.00
EBITDA
76,826.00
12,236.00
59,224.00
87,980.00
37,295.00
Other Operating Expense
-
-
-
44,957.00
-
Non-Operating Interest Income
934.00
275.00
169.00
77.00
21.00

About Affymax

View Profile
Address
630 Fifth Avenue
New York New York 10020
United States
Employees -
Website http://www.affymax.com
Updated 07/08/2019
Affymax, Inc. is a biopharmaceutical company. The company was founded on July 20, 2001 and is headquartered in New York, NY. .